Aggregates in monoclonal antibody manufacturing processes

Biotechnology and Bioengineering

Volumn 108, Issue 7, 2011, Pages 1494-1508

  Vázquez Rey, María ^a   Lang, Dietmar A ^b  

^a Manufacturing Science and Technology   (Spain)

^b LONZA AG   (Switzerland)

Author keywords

Aggregates; Manufacturing processing; Monoclonal antibody

Indexed keywords

ANTIBODY MANUFACTURING; BIOLOGICAL ACTIVITIES; COMPLEX ACTIVITY; DRUG SUBSTANCES; INDUSTRIAL PRODUCTION; KEY FACTORS; LARGE-SCALE MANUFACTURING; MANUFACTURING PROCESS; MANUFACTURING PROCESSING; PROTEIN AGGREGATION; QUALITY ATTRIBUTES; THERAPEUTIC PRODUCTS; THERAPEUTIC PROPERTIES; THERAPEUTIC PROTEIN;

AGGREGATES; ALLERGIES; DRUG PRODUCTS; INDUSTRIAL ENGINEERING; MERGERS AND ACQUISITIONS; MONOCLONAL ANTIBODIES; PRODUCTION ENGINEERING; SURFACE PLASMON RESONANCE;

MANUFACTURE;

BUFFER; MONOCLONAL ANTIBODY; PROTEIN A; SURFACTANT;

CELL CULTURE; CHROMATOGRAPHY; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG STORAGE; FREEZING; PH; PROTEIN AGGREGATION; PUMP; REVIEW; THAWING; ULTRAFILTRATION;

ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; HUMANS; PROTEIN DENATURATION; PROTEIN STABILITY; RECOMBINANT PROTEINS; TECHNOLOGY, PHARMACEUTICAL;

EID: 79956103081     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.23155     Document Type: Review

References (134)

1. Andrews JM, Roberts CJ. 2007. A Lumry-Eyring nucleated-polymerization (LENP) model of protein aggregation kinetics I. Aggregation with preequilibrated unfolding. J Phys Chem B 111(27): 7897-7913.
2. Andya JD, Hsu CC, Shire SJ. 2003. Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS Pharm Sci 5(2): 21-35.
3. Ansaldi D, Lester P. Separation of polypeptide monomers. US patent 6 620 918. September 16, 2003.
4. Bam NB, Cleland JL, Yang J, Manning MC, Carpenter JF, Kelley RF. 1998. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J Pharm Sci 87(12): 1554-1559.
5. Bee JS, Davies M, Freund E, Carpenter JF, Randoplh TW. 2009a. Aggregation of a monoclonal antibody induced by adsorption to stainless steel. Biotechnol Bioeng 105(1): 121-129.
6. Bee JS, Stevenson JL, Mehta B, Svitel J, Pollastrini J, Platz R. 2009b. Response of a concentrated monoclonal antibody formulation to high shear. Biotechnol Bioeng 103(5): 936-943.
7. Bhatnagar BS, Bogner RH, Pikal MJ. 2007. Protein stability during freezing: Separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol 12(5): 505-523.
8. Biddlecombe JG, Craig AV, Zhang H, Uddin S, Mulot S, Fish BC, Bracewell DG. 2007. Determining antibody stability: Creation of solid-liquid interfacial effects within a high shear environment. Biotechnol Prog 23(5): 1218-1222.
9. Birch JR, Racher AJ. 2006. Antibody production. Adv Drug Deliv Rev 58(5-6): 671-685.
10. Bodalo A, Gomez JL, Gomez E, Maximo MF, Montiel MC. 2004. Study of L-aminoacylase deactivation in an ultrafiltration membrane reactor. Enzyme Microb Technol 35(2-3): 261-266.
11. Brych SR, Gokarn YR, Hultgen H, Stevenson RJ, Rajan R, Matsumura M. 2010. Characterization of antibody aggregation: Role of buried, unpaired cysteines in particle formation. J Pharm Sci 99(2): 764-781.
12. Bywater R, Eriksson GB, Ottosson T. 1983. Desorption of immunoglobulins from Protein A-Sepharose Cl-4B under mild conditions. J Immunol Methods 64(1-2): 1-6.
13. Carpenter JF, Crowe JH. 1989. An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. Biochemistry 28: 3916-3922.
14. Carpenter JF, Prestrelski SJ, Arakawa T. 1993. Separation of freezing- and drying-induced denaturation of lyophilized proteins using stress-specific stabilization. I. Enzyme activity and calorimetric studies. Arch Biochem Biophys 303: 456-464.
15. Carpenter JF, Kendrick BS, Chang BS, Manning MC, Randolph TW. 1999. Inhibition of stress-induced aggregation of protein therapeutics. Methods Enzymol 309: 236-255.
16. Chandavarkar AS. 1990. Dynamics of fouling of microporous membranes by proteins. Cambridge, MA: Massachusetts Institute of Technology, p. 284.
17. Chang BS, Kendrick BS, Carpenter JF. 1996. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J Pharm Sci 85(12): 1325-1361.
18. Chang L, Shepherd D, Sun J, Ouellette D, Grant KL, Tang X, Pikal MJ. 2005. Mechanism of protein stabilization by sugars during freeze-drying and storage: Native structure preservation, specific interaction, and/or immobilization in a glassy matrix? J Pharm Sci 94(7): 1427-1444.
19. Chen T. 1992. Formulation concerns of protein drugs. Drug Dev Ind Pharm 18(11-12): 1311-1354.
20. Chi EY, Krishnan S, Kendrick BS, Chang BS, Carpenter JF, Randolph TW. 2003. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci 12(5): 903-913.
21. Colombie S, Gaunand A, Lindet B. 2001. Lysozyme inactivation under mechanical stirring: Effect of physical and molecular interfaces. Enzyme Microb Technol 28(9-10): 820-826.
22. Córdoba-Rodríguez RV. 2008. Aggregates in mAb and recombinant therapeutic proteins: A regulatory perspective FDA perspectives on specifications and effective control strategies. Biopharm Int 21(11): 44-53.
23. Creed D. 1984. The photophysics and photochemistry of the near-UV absorbing amino acids. II. Tyrosine and its simple derivatives. Photochem Photobiol 39(4): 563-575.
24. Cromwell EM, Hilario E, Jacobson F. 2006. Protein aggregation and bioprocessing. AAPS J 8(3): Article 66.
25. Doms RW, Heleniuss A, White J. 1985. Membrane fusion activity of the influenza virus hemagglutinin. The low pH-induced conformational change. J Biol Chem 260(5): 2973-2981.
26. Eckhardt BM, Oeswein JQ, Bewley TA. 1991. Effect of freezing on aggregation of human growth hormone. Pharm Res 8(11): 1360-1364.
27. European Pharmacopoeia. 2006a. 5. Edition 5. 05. Parenteral preparations. Strasbourg, France: EDQM Council of Europe.
28. European Pharmacopoeia. 2006b. 5. Edition 5. 05. 2. 9. 20. Particulate contamination: Visible particles. Strasbourg, France: EDQM Council of Europe.
29. European Pharmacopoeia. 2006c. 5. Edition 5. 05. 2. 9. 19. Particulate contamination: Sub-visible particles. Strasbourg, France: EDQM Council of Europe.
30. Faherner RL, Knudsen HL, Basey CD, Galan W, Feuerhelm D, Vanderlaan M. 2001. Industrial purification of pharmaceutical antibodies: Development, operation, and validation of chromatography processes. Biotechnol Genet Eng Rev 18: 301-327.
31. Fesinmeyer RM, Hogan S, Saluja A, Brych SR, Kras E, Narhi LO. 2009. Effect of ions on agitation- and temperature-induced aggregation reactions of antibodies. Pharm Res 26(4): 903-913.
32. Franco R, Daniela G, Fabrizio M, Ilaria G, Detlev H. 1999. Influence of osmolarity and pH increase to achieve a reduction of monoclonal antibodies aggregates in a production process. Cytotechnology 29(1): 11-25.
33. Franks F. 1982. The properties of aqueous solutions at subzero temperatures. In: Franks F. editor. Water: A comprehensive treatise, vol. 7, New York: Plenum Press.
34. Franks F, Hatley RHM, Mathias SF. 1991. Materials science and the production of shelf-stable biologicals. Biopharmaceutics 4(9): 40-42, 55.
35. Gabrielson JP, Brader ML, Pekar AH, Mathis KB, Winter G, Carpenter JF. 2007. Quantification of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. J Pharm Sci 96(2): 268-279.
36. Gagnon P. 1995. Purification Tools for Monoclonal Antibodies. Validated Biosystems. 55-163.
37. Gagnon P. 2008. Antibody aggregate removal by hydroxyapatite chromatography in the presence of polyethylene glycol. J Immunol Methods 336(2): 222-228.
38. Gagnon P. 2009a. IgG aggregate removal by charged-hydrophobic mixed mode chromatography. Curr Pharm Biotechnol 10(4): 434-439.
39. Gagnon P. 2009b. Monoclonal antibody purification with hydroxyapatite. New Biotechnol 25(5): 287-293.
40. Gokarn YR, Kras E, Nodgaard C, Dharmavaram V, Fesinmeyer RM, Hultgen H, Brych S, Remmele RL, Brems DN, Hershenson S. 2008. Self-buffering antibody formulations. J Pharm Sci 97(8): 3051-3066.
41. Gomme PT, Hunt BM, Tatford OC, Johnston A, Bertolini J. 2006a. Effect of lobe pumping on human albumin: Investigating the underlying mechanisms of aggregate formation. Biotechnol Appl Biochem 43(2): 103-111.
42. Gomme PT, Prakash M, Hunt B, Stokes N, Cleary P, Tatford OC. 2006b. Effect of lobe pumping on human albumin: Development of a lobe pump simulator using smoothed particle hydrodynamics. Biotechnol Appl Biochem 43(2): 113-120.
43. Gulich S, Uhlen M, Hober S. 2000. Protein engineering of an IgG-binding domain allows milder elution conditions during affinity chromatography. J Biotechnol 76(2-3): 233-244.
44. Harding MM, Ward LG, Haymet ADJ. 1999. Type I 'antifreeze' proteins: Structure-activity studies and mechanisms of ice growth inhibition. Eur J Biochem 264(3): 653-665.
45. Harinarayan C, Mueller J, Ljunglöf A, Fahrner R, Van Alstine J, Van Reis R. 2006. An exclusion mechanism in ion exchange chromatography. Biotechnol Bioeng 95(5): 775-787.
46. Harris RJ, Shire SJ, Winter C. 2004. Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies. Drug Dev Res 61(3): 137-154.
47. Harrison JS, Gill A, Hoare M. 1998. Stability of a single-chain Fv antibody fragment when exposed to a high shear environment combined with air-liquid interfaces. Biotechnol Bioeng 59: 517-519.
48. Harrison RG, Todd P, Rudge SR, Petrides DP. 2003. Bioseparations science and engineering. New York: Oxford University Press, p. 31-35.
49. Hawe A, Kasper JC, Friess W, Jiskoot W. 2009. Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress. Eur J Pharm Sci 38(2): 79-87.
50. Heller MG, Carpenter JF, Randolph TW. 1997. Manipulation of lyophilization-induced phase separation: Implications for pharmaceutical proteins. Biotechnol Prog 13(5): 590-596.
51. Horowitz B, Lazo A, Grossberg H, Page G, Lippin A, Swan G. 1998. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang 74 (Suppl 1): 203-206.
52. Imamura K, Shimomura M, Nagai S, Akamatsu M, Nakanish K. 2008. Adsorption characteristics of various proteins to a titanium surface. J Biosci Bioeng 106(3): 273-278.
53. Jiang C, Flansburg L, Ghose S, Jorjorian P, Shukla AA. 2010. Defining process design space for a hyrophobic interaction chromatography purification step: Application by quality by design principles. Biotechnol Bioeng 107(6): 985-997.
54. Jones LS, Kaufmann A, Middaugh CR. 2005. Silicone oil induced aggregation of proteins. J Pharm Sci 94: 918-927.
55. Kameoka D, Masuzaki E, Ueda T, Imoto T. 2007. Effect of buffer species on the unfolding and the aggregation of humanized IgG. J Biochem 142(3): 383-391.
56. Kendrick BS, Carpenter JF, Cleland JL, Randolph TW. 1998a. A transient expansion of the native state precedes aggregation of recombinant human interferon-γ. Proc Natl Acad Sci USA 95: 14142-14146.
57. Kendrick B, Cleland JF, Lam X, Nguyen T, Randolph TW, Manning MC. 1998b. Aggregation of recombinant human interferon gamma: Kinetics and structural transitions. J Pharm Sci 87(9): 1069-1076.
58. Kendrick BS, Li T, Chang BS. 2002. Physical stabilization of proteins in aqueous solution. In: Carpenter JF, Manning MC, editors. Rational design of stable protein formulations. Theory and practice. Pharmaceutical biotechnology. Vol. 13. New York: Kluwer Academic/Plenum Publishers, pp. 61-84.
59. Kiefhaber T, Rudolph R, Kohler HH, Buchner J. 1991. Protein aggregation in vitro and in vivo: A quantitative model of the kinetic competition between folding and aggregation. Nat Biotechnol 9(9): 825-829.
60. Kiese S, Pappenberger A, Friess W, Mahler HC. 2008. Shaken, not stirred: Mechanical stress testing of an IgG1 antibody. J Pharm Sci 97(10): 4347-4366.
61. Kiese S, Pappenberger A, Friess W, Mahler HC. 2010. Equilibrium studies of protein aggregates and homogeneous nucleation in protein formulation. J Pharm Sci 99: 632-644.
62. Knutson DW, Kijlstra A, Lentz H, Van Es LA. 1979. Isolation of stable aggregates of IgG by zonal ultracentrifugation in sucrose gradients containing albumin. Imunol Invest 8(3): 337-345.
63. Kohle P, Badkar A. 2010. Protein and solute distribution in drug substance containers during frozen storage and post-thawing: A tool to understand and define freezing-thawing parameters in biotechnology process development. Biotechnol Prog 27(2): 494-504.
64. Kozlowski S, Swann P. 2006. Current and future issues in manufacturing and development of monoclonal antibodies. Adv Drug Deliv Rev 58(5-6): 707-722.
65. Kramarczyk JF, Kelley BD, Coffman JL. 2008. High-throughput screening of chromatographic separations: II. Hydrophobic interaction. Biotechnol Bioeng 100(4): 707-720.
66. Krishnamurthy R, Manning MC. 2002. The stability factor: Importance in formulation development. Curr Pharm Biotechnol 3(4): 361-371.
67. Kueltzo LA, Wang W, Randolph TW, Carpenter JF. 2008. Effects of solution conditions, processing parameters, and container materials on aggregation of a monoclonal antibody during freeze-thawing. J Pharm Sci 97(5): 1801-1812.
68. Lam XM, Yang JY, Cleland JL. 1997. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci 86(11): 1250-1255.
69. Lehr HA, Brunner J, Rangoonwala R, Kirkpatrick CJ. 2002. Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in post-ischemic striated muscle. Am J Respir Crit Care Med 165(4): 514-520.
70. Litzen A, Walter JK, Krischollek H, Wahlund KG. 1993. Separation and quantitation of monoclonal antibody aggregates by asymmetrical flow field-flow fractionation and comparison to gel permeation chromatography. Anal Biochem 212(2): 469-480.
71. Liu J, Nguyen MD, Andya JD, Shire SJ. 2005. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci 94(9): 1928-1940.
72. Lu Y, Williamson B, Gillespie R. 2009. Recent advancement in application of hydrophobic interaction chromatography for antibody aggregate removal in industrial purification process. Curr Pharm Biotechnol 10(4): 427-433.
73. Lumry R, Eyring H. 1954. Conformation changes of proteins. J Phys Chem 58: 110-120.
74. Lund M, Jonsson B. 2003. A mesoscopic model for protein-protein interactions in solution. Biophys J 85: 2940-2947.
75. Mahler HC, Muller R, Friess W, Delille A, Matheus S. 2005. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm 59(3): 407-417.
76. Mahler HC, Friess W, Grauschopf U, Kiese S. 2009. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci 98(9): 2909-2934.
77. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. 2010. Stability of protein pharmaceuticals: An update. Pharm Res 27(4): 544.
78. Meireles M, Aimar P, Sanchez V. 1991. Albumin denaturation during ultrafiltration: Effects of operating conditions and consequences on membrane fouling. Biotechnol Bioeng 38(5): 528-534.
79. Moore JM, Patapoff TW, Cromwell ME. 1999. Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor. Biochemistry 38(42): 13960-13967.
80. Morris AM, Watzky MA, Finke RG. 2009. Protein aggregation kinetics, mechanism, and curve-fitting: A review of the literatura. Biochim Biophys Acta 1794: 375-397.
81. Nakanishi K, Sakiyama T, Imamura K. 2001. On the adsorption of proteins on solid surfaces, a common but very complicated phenomenon. J Biosci Bioeng 91(3): 233-244.
82. Narendranathan TJ, Dunnill P. 1982. The effect of shear on globular proteins during ultrafiltration: Studies of alcohol dehydrogenase. Biotechnol Bioeng 24(9): 2103-2107.
83. Neumaier R. 2000. Hermetic pumps: The latest innovations and industrial applications of sealless pumps. Houston: Farmont Press, pp. 391-399.
84. Patel J, Kothari R, Tunga R, Ritter NM, Tunga BS. 2011. Stability considerations for biopharmaceuticals, Part 1 overview of protein and peptide degradation pathways. Bioprocess Int 20-31.
85. Phillips J, Drumm A, Harrison P, Bird P, Bhamra K, Berrie E. 2001. Manufacture and quality control of CAMPATH-1 antibodies for clinical trials. Cytotherapy 3(3): 233-242.
86. Philo JS. 2006. Is any measurement method optimal for all aggregate sizes and types? AAPS J 8(3): E564-E571.
87. Pikal-Cleland KA, Carpenter JF. 2001. Lyophilization-induced protein denaturation in phosphate buffer systems: Monomeric and tetrameric b, galactoside. J Pharm Sci 90(9): 1255-1268.
88. Powers ET, Powers DL. 2006. The kinetics of nucleated polymerizations at high concentrations: Amyloid fibril formation near and above the "supercritical concentration". Biophys J 91(1): 122-312.
89. Rathore AS. 2009. Roadmap for implementation of quality by design for biotechnology products. Trends Biotechnol 27(9): 546-553.
90. Rathore AS, Winkle E. 2010. Quality by design for biopharmaceuticals. Nat Biotechnol 27(1): 26-34.
91. Ray S, Tarrach K. 2009. Virus clearance strategy using a three-tier orthogonal technology platform. Biopharm Int 22: 50-58.
92. Remmele RL, Nightlinger NS, Srinivasan S, Gombotz WR. 1998. Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry. Pharm Res 15(2): 200-208.
93. Remmele JR, Callahan WJ, Krishnan S, Zhou L, Bondarenko PV, Nichols AC. 2006. Active dimer of Epratuzumab provides insight into the complex nature of antibody aggregate. J Pharm Sci 95(1): 126-145.
94. Roberts CJ. 2007. Non-native protein aggregation kinetics. Biotechnol Bioeng 98: 927-938.
95. Rosenberg AS. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8(3): Article 59.
96. Rosenberg E, Hepbildikler S, Kuhne W, Winter G. 2009. Ultrafiltration concentration of monoclonal antibody solutions: Development of an optimized method minimizing aggregation. J Membr Sci 342(1-2): 50-59.
97. Sánchez-Ruiz JM. 2010. Protein kinetic stability. Biophys Chem 148: 1-15.
98. Scolnik PA. 2009. mAbs a business perspective. mAbs 1(2): 179-184.
99. Serno T, Carpenter JF, Randolph TW, Winter G. 2010. Inhibition of agitation-induced aggregation of an IgG-antibody by hydroxyl-beta-cyclodextrin. J Pharm Sci 99(3): 1193-1206.
100. Sharma B. 2007. Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changes. Biotechnol Adv 25(3): 325-331.
101. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93(6): 1390-1402.
102. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. 2007. Downstream processing of monoclonal antibodies-Application of platform approaches. J Chrom B 848(2007): 28-39.
103. Singh SK. 2010. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 100(2): 354-387.
104. Slade L, Levine H. 1991. Beyond water activity: Recent advances based on an alternative approach to the assessment of food quality and safety. Crit Rev Food Sci Nutr 30: 115-360.
105. Sluzky V, Tamada JA, Klibanov AM, Langer R. 1991. Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc Natl Acad Sci USA 88(21): 9377-9381.
106. Sluzky V, Klibanov AM, Langer R. 1992. Mechanism of insulin aggregation and stabilization in agitated aqueous solutions. Biotechnol Bioeng 40(8): 895-903.
107. Sofer G. 2002. Virus inactivation in the 90's and in the 21st century. Biopharm Int 1: 50-57.
108. Sommerfeld S, Strube J. 2005. Challenges in biotechnology production-Generic processes and process optimization for monoclonal antibodies. Chem Eng Process 44(1): 101-114.
109. Strambini GB, Gabellieri E. 1996. Proteins in frozen solutions: Evidence of ice-induced partial unfolding. Biophys J 70(2): 971-976.
110. Striolo A, Bratko D, Wu JZ, Elvassore N, Blanch HW, Prausnitz JM. 2002. Forces between aqueous non uniformly charged colloids from molecular simulation. J Chem Phys 116(17): 7733-7743.
111. Suda EJ, Thomas KE, Pabst TM, Mensah P, Ramasubramanyan N, Gustafson ME. 2009. Comparison of agarose and dextran-grafted agarose strong ion exchangers for the separation of protein aggregates. J Chromatogr A 1216(27): 5256-5264.
112. Thirumangalathu R, Krishnan S, Ricci MS, Brems DN, Randolph TW, Carpenter JF. 2009. Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J Pharm Sci 98(9): 3167-3181.
113. Thomas CR, Geer D. 2011. Effects of shear in proteins in solution. Biotechnol Lett 33: 443-456.
114. Treuheit MJ, Kosky AA, Brems DN. 2002. Inverse relationship of protein concentration and aggregation. Pharm Res 19(4): 511-516.
115. Tyagi AK, Randolph TW, Dong A, Maloney KM, Hitscherich C, Carpenter JF. 2009. IgG particle formation during filling pump operation: A case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci 98(1): 94-104.
116. Van Beers MMC, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W. 2010. Aggregated recombinant human interferon beta induces antibodies but no memory in immune-tolerant transgenic mice. Pharm Res 27: 1812-1824.
117. Van Den Berg L. 1996. pH changes in buffers and foods during freezing and subsequent storage. Cryobiology 3(3): 236-242.
118. Van Reis R, Zydney A. 2001. Membrane separations in biotechnology. Curr Opin Biotechnol 12(2): 208-211.
119. Van Reis R, Zydney A. 2007. Bioprocess membrane technology. J Membr Sci 297: 16-50.
120. Van Reis R, Goodrich EM, Yson CL, Frautschy LN, Dzengeleski S, Lutz H. 1997. Linear scale ultrafiltration. Biotechnol Bioeng 55(5): 737-746.
121. Vermeer AWP, Norde W. 2000. The thermal stability of immunoglobulin: Unfolding and aggregation of a multi-domain protein. Biophys J 78(1): 394-404.
122. Wan M, Wang GY. Enhanced aggregate removal from bulk biologicals using ion exchange chromatography. US Patent 6177548. January 23, 2001.
123. Wan Y, Vasan S, Ghosh R, Hale G, Cui Z. 2005. Separation of monoclonal antibody Alemtuzumab monomer and dimers using ultrafiltration. Biotechnol Bioeng 90(4): 422-432.
124. Wang W. 2005. Protein aggregation and its inhibition in bio-pharmaceutics. Int J Pharm 289(1-2): 1-30.
125. Wang L, Hale G, Ghosh R. 2006. Non-size-based membrane chromatographic separation and analysis of monoclonal antibody aggregates. Anal Chem 78(19): 6863-6867.
126. Wang W, Singh S, Zeng DL, King K, Nema S. 2007. Antibody structure, instability, and formulation. J Pharm Sci 96(1): 1-26.
127. Wang X, Das TK, Singh SK, Kumar S. 2009. Potential aggregation prone regions in biotherapeutics. mAbs 1(3): 1-14.
128. Wang W, Nema S, Teagarden D. 2010. Protein aggregation-Pathways and influencing factors. J Pharm Sci 390: 89-99.
129. Webb SD, Webb JN, Hughes TG, Sesin DF, Kincaid AC. 2002. Freezing biopharmaceuticals using common techniques and the magnitude of bulk-scale freeze-concentration. Biopharmaceutics 15(5): 22-34.
130. Xia X. 2007. Bioinformatics and the cell: Modern computational approaches in genomics, proteomics and transcriptomics. US: Springer, pp. 207-212.
131. Yao Y, Lenhoff AM. 2006. Pore size distributions of ion exchangers and relation to protein binding capacity. J Chromatogr A 1126(1-2): 107-119.
132. Yigzaw Y, Piper R, Tran M, Shukla A. 2006. Exploitation of the adsorptive properties of depth filters for host cell protein removal during mAb purification. Biotechnol Prog 22(1): 288-296.
133. Yu LX. 2007. Pharmaceutical quality by design: Product and process development, understanding and control. Pharm Res 25(4): 781-791.
134. Zhang YB, Howitt J, McCorkle S, Lawrence P, Springer K, Freimuth P. 2004. Protein aggregation during overexpression limited by peptide extensions with large net negative charge. Protein Expr Purif 36(2): 207-216.